

Oxymetazoline

Selected References:

- Arendt KW, et al. 2011. Topical vasoconstrictor use for nasal intubation during pregnancy complicated by cardiomyopathy and preeclampsia. *Int J Obstet Anesth.* 20(3):246-9.
- Aselton P, et al. 1985. First-trimester drug use and congenital disorders. *Obstet Gynecol* 65:451-455, 1985.
- Baxi LV, et al. 1985. Fetal heart rate changes following maternal administration of a nasal decongestant. *Am J Obstet Gynecol.* 153:799-800.
- Jick H, et al. 1981. First-trimester drug use and congenital disorders. *JAMA* 246:343-346.
- Mazzotta P, et al. 1999. Treating allergic rhinitis in pregnancy. Safety considerations. *Drug Saf.* 20(4):361-75.
- Menezes GA, et al. 2016. Prenatal diagnosis and physical model reconstruction of agnathia-otocephaly with limb deformities (absent ulna, fibula and digits) following maternal exposure to oxymetazoline in the first trimester. *J Obstet Gynaecol Res.* 42(8):1016-20.
- Rayburn WF, et al. 1990. Uterine and fetal Doppler flow changes from a single dose of a long-acting intranasal decongestant. *Obstet Gynecol.* 76:180-2.
- Yau W-P, et al. 2013. Use of decongestants during pregnancy and the risk of birth defects. *Am J Epidemiol.* 178(2):198-208.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mai 2025.

Oxymetazoline

Selected References:

- Bryant Ranch Prepack. 2024. Hydroxyzine Hydrochloride Product Label. Available at:

<https://www.accessdata.fda.gov/spl/data/897a39b6-65b1-4e52-85e9-2650d23a4dc0/897a39b6-65b1-4e52-85e9-2650d23a4dc0.xml>. Accessed 14 April 2025.

- Calderon-Margalit, R., Qiu, C., Ornoy, A., Siscovick, D. S., & Williams, M. A. 2009. Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. *American journal of obstetrics and gynecology*, **201**(6), 579.e1-579.e5798.
- Diav-Citrin O, et al. 2003. Pregnancy outcome after gestational exposure to loratidine or antihistamines: a prospective controlled cohort study. *J Allergy Clin Immunol* 111:1239-1243.
- Earl FL, et al. 1973. Teratogenic research in beagle dogs and miniature swine. *Lab Anim Drug Test Symp Int Comm Lab Anim*, 5th Fischer, Stuttgart pp. 233-247.
- Einarson A, et al. 1997. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. *Ann Allergy Asthma Immunol* 78:183-186.
- Erez S, et al. 1971. Double-blind evaluation of hydroxyzine as an antiemetic in pregnancy. *J Reprod Med* 7:57-59.
- Ito S, et al. 1993. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. *Am J Obstet Gynecol* 168:1393-1399.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mai 2025.

Oxymetazoline

Selected References:

- Andersen JT, et al. 2016. Diclofenac/misoprostol during early pregnancy and the risk of miscarriage: a Danish nationwide cohort study. *Arch Gynecol Obstet* 294(2): 245-250.
- Cassina M, et al. 2010. First trimester diclofenac exposure and pregnancy outcome. *Reprod Toxicol* 30:401-404.
- Choi E-Y, et al. 2023. Neonatal and maternal adverse outcomes and exposure to nonsteroidal anti-inflammatory drugs during early pregnancy in South Korea: a nationwide cohort study. *PLoS Med*, 20(2):e1004183.
- Dawood MY. 1993. Nonsteroidal anti-inflammatory drugs and reproduction. *Am J Obstet Gynecol*,

169(5):1255-1265.

- Daniel S, et al. 2012. Major malformations following exposure to Nonsteroidal anti-inflammatory drugs during the first trimester of pregnancy. *J Rheumatol* 39(11): 2163-2169.
- Daniel S, et al. 2014. Fetal exposure to nonsteroidal anti-inflammatory drugs and spontaneous abortion. *Can Med Assoc J* 186(5):E177-E182.
- Daniel S, et al. 2015. NSAIDs and spontaneous abortions – true effect or an indication bias? *Br J Clin Pharmacol*, 80(4):750-754.
- Dathe K, et al. 2018. No evidence of adverse pregnancy outcome after exposure to ibuprofen in the first trimester—Evaluation of the national Embryotox cohort. *Reproductive Toxicology*, 79: 32-38.
- Ericson A and Kallen BA. 2001. Nonsteroidal anti-inflammatory drugs in early pregnancy. *Reprod Toxicol*, 15:371-
- Janssen NM and Genta MS. 2000. The effects of immunosuppressive and anti-inflammatory medication on fertility, pregnancy, and lactation. *Arch Intern Med*, 160:610-619.
- Nakhai-Pour HR, et al. 2011. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. *CMAJ*. 183(15):1713-1720.
- Nezvalova-Henriksen K et al. 2013. Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective study. *BJOG*, 120(8):948-959.
- Nielsen GL, et al. 2001. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. *BMJ*, 322(7281):266-270.
- Nielsen GL, et al. 2004. Danish group reanalyses miscarriage in NSAID users. *BMJ*, 328(7431):109.
- Ofori B, et al. 2006. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: a nested case-control study. *Birth Defects Res B Dev Reprod Toxicol* 77:268-279.
- Padberg S, et al. 2018. Safety of diclofenac use during early pregnancy: A prospective observational cohort study. *Reprod Toxicol*. 77:122-129.
- Phadke V, et al. 2012. Maternal ingestion of diclofenac leading to renal failure in newborns. *Pediatr Nephrol*. 27(6):1033-1036.
- S. Food and Drug Administration. 2020. FDA Warns that Using a Type of Pain and Fever Medication in Second Half of Pregnancy Could Lead to Complications. Available at: https://www.fda.gov/news-events/press-announcements/fda-warns-using-type-pain-and-fever-medication-second-half-pregnancy-could-lead-complications?utm_medium=email&utm_source=govdelivery Accessed 2 Dec 2024.
- Scherneck S, et al. 2015. Reversible oligohydramnios in the second trimester of pregnancy in two patients with long-term diclofenac exposure. *Reprod Toxicol*. 58:61-64.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mai 2025.

Oxymetazoline

Selected References:

- Andersen HJ. 1983. Excretion of verapamil in human milk. *Eur J Clin Pharmacol*, 25:279-80.
- Anderson P, et al. 1987. Verapamil and norverapamil in plasma and breast milk during breast feeding. *Eur J Clin Pharmacol*, 31:625-627.
- Belfort MA, et al. 1990. Hemodynamic changes associated with intravenous infusion of the calcium antagonist verapamil in the treatment of severe gestational proteinuric hypertension. *Obstet Gynecol*, 75:970-974.
- Benoff S, et al. 1994. The effect of calcium ion channel blockers on sperm fertilization potential. *Fertil Steril*, 62:606-617.
- Byerly WG, et al. 1991. Verapamil in the treatment of maternal paroxysmal supraventricular tachycardia. *Ann Emerg Med*, 20(5):552-554.
- Czeizel AE, Rockenbauer M. 1997. Population-based case-control study of teratogenic potential of corticosteroids. *Teratology*, 56:335-340.
- Czeizel AE, Toth M. 1998. Birth weight, gestational age and medications during pregnancy. *Int J Gynaecol Obstet*, 60:245-249.
- Fearrington EL, et al. 1983. Hyperprolactinemia-galactorrhea induced by verapamil. *Am J Cardiol*, 51:1466-1467.
- Gluskin LE, et al. 1981. Verapamil-induced hyperprolactinemia and galactorrhea. *Ann Intern Med*, 95:66-67.
- Inoue H. 1984. Excretion of verapamil in human milk. *Br Med J*, 288:645-646.
- Joglar JA, et al. 2023. HRS expert consensus statement on the management of arrhythmias during pregnancy. *Heart Rhythm*. 20: e175-264.
- Katsoff D, Check JH. 1997. A challenge to the concept that the use of calcium channel blockers causes reversible male infertility. *Hum Reprod*, 12(7):1480-482.
- King BD, et al. 1983. Impotence during therapy with verapamil. *Arch Intern Med*, 143:1248-1249.
- Magee LA, et al. 1996. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. *Am J Obstet Gynecol*, 174(3):823-828.
- Miller MR, et al. 1986. Verapamil and breast-feeding. *Eur J Clin Pharmacol*, 30:125-126.
- Murad SHN, et al. 1985. Effects of verapamil on uterine blood flow and maternal cardiovascular function in the awake pregnant ewe. *Anesth Analg*, 64:7-10.
- Spelger G, et al. 1980. Kardiale Parameter beim Neugeborenen nach Tokolyse [Cardiac parameters of the newborn after tocolysis (author's transl)]. *Klin Padiatr*, 192(4):319-324. German.
- Tamirisa KP, 2022. Arrhythmias and Heart Failure in Pregnancy: A Dialogue on Multidisciplinary Collaboration. *J Cardiovasc Dev Dis*, 9:199.
- Tektemur A, et al. 2020. Verapamil-induced ion channel and miRNA expression changes in rat testis and/or spermatozoa may be associated with male infertility. *Andrologia*, 52(10):e13778.
- Weber-Schoendorfer C, et al. 2008. The safety of calcium channel blockers during pregnancy: a prospective,

multicenter, observational study. *Reprod Toxicol*, 2008;26:24-30.

- 2025. Product labeling.
<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3283bba6-05dd-3766-e063-6394a90ada69>

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mai 2025.

Oxymetazoline

Selected References:

- An Y, et al. 2014. The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. *Clin Endocrinol (Oxf)*, 80(3):425-431.
- Chan E. 1993. Displacement of bilirubin from albumin by berberine. *Biol Neonate*, 63:201-208.
- Di Pierro F, et al. 2023. Effect of Berberine Phytosome on reproductive, dermatologic, and metabolic characteristics in women with polycystic ovary syndrome: a controlled, randomized, multi-centric, open-label clinical trial. *Frontiers in pharmacology*, 14:1269605.
- Ha S & Song X. 2024. Berberine as adjuvant therapy for treating reduced fertility potential in women with polycystic ovary syndrome: A meta-analysis of randomized controlled trials. *Explore (New York, N.Y.)*, 20(6):103040
- Imanshahidi M, et al. 2008. Pharmacological and therapeutic effects of *Berberis vulgaris* and its active constituent, berberine. *Phytother Res*, 22:999-1012.
- Lampe KF. 1999. Berberine. In DeSmet PAGM, Keller K, Hnsel R, Chandler RF. *Adverse effects of herbal drugs*, vol 1: 97-103. Springer-Verlag, Berlin.
- Zhao S, et al. 2021. Effect and mechanism of berberine against polycystic ovary syndrome. *Biomedicine & Pharmacotherapy*, 138:111468.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mai 2025.